Eli Lilly and Company (NYSE:LLY) Stock Price Up 2.3% Following Analyst Upgrade

Eli Lilly and Company (NYSE:LLY) shares traded up 2.3% on Thursday after Jefferies Financial Group raised their price target on the stock from $1,300.00 to $1,330.00. The company traded as high as $1,047.30 and last traded at $1,041.8910. 2,699,576 shares changed hands during trading, a decline of 15% from the average session volume of 3,185,233 shares. The stock had previously closed at $1,018.87.

Several other research firms also recently weighed in on LLY. Weiss Ratings downgraded Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday. Rothschild & Co Redburn raised their price objective on Eli Lilly and Company from $880.00 to $900.00 in a research note on Thursday, May 7th. Berenberg Bank lifted their target price on Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a report on Thursday, February 19th. Wells Fargo & Company upped their target price on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Finally, Loop Capital set a $1,200.00 price target on shares of Eli Lilly and Company in a report on Tuesday, February 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $1,220.37.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Goldman Sachs reaffirmed its Buy rating on LLY and raised its price target to $1,283, signaling confidence in further upside. MarketScreener Latest Ratings
• Positive Sentiment: Jefferies lifted its price target on Eli Lilly to $1,330, also implying meaningful upside from recent trading levels. MarketScreener
• Positive Sentiment: New clinical updates across Lilly’s pipeline, including positive obesity conference data, Alzheimer’s study progress, and a new heart-failure trial, help reinforce the market’s view that Lilly has multiple growth drivers beyond its current diabetes and obesity drugs.
• Neutral Sentiment: Lilly also announced an acquisition of Engage Biologics, extending its gene-therapy ambitions; this supports long-term diversification, but the near-term stock impact is less direct. Eli Lilly’s Engage Biologics Deal Extends Genetic Bets Beyond Obesity Boom

Hedge Funds Weigh In On Eli Lilly and Company

Institutional investors and hedge funds have recently modified their holdings of the stock. Summitry LLC grew its holdings in Eli Lilly and Company by 76.0% during the first quarter. Summitry LLC now owns 1,477 shares of the company’s stock worth $1,358,000 after acquiring an additional 638 shares during the period. WNY Asset Management LLC acquired a new position in Eli Lilly and Company in the first quarter valued at approximately $5,121,000. Coastline Complete Wealth LLC lifted its holdings in Eli Lilly and Company by 1.1% in the first quarter. Coastline Complete Wealth LLC now owns 990 shares of the company’s stock valued at $910,000 after acquiring an additional 11 shares during the period. Wellington Grp LLC boosted its position in Eli Lilly and Company by 4.4% in the 1st quarter. Wellington Grp LLC now owns 12,159 shares of the company’s stock worth $11,183,000 after purchasing an additional 508 shares in the last quarter. Finally, Essential Partners LLC boosted its position in Eli Lilly and Company by 32.0% in the 1st quarter. Essential Partners LLC now owns 293 shares of the company’s stock worth $270,000 after purchasing an additional 71 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 2.4%

The firm has a market cap of $1.00 trillion, a price-to-earnings ratio of 37.89, a PEG ratio of 1.13 and a beta of 0.48. The business’s 50 day moving average price is $942.87 and its 200 day moving average price is $1,003.77. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. During the same period in the previous year, the business posted $3.34 EPS. The business’s revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 35.82 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a $1.73 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.